Prime Medicine (NYSE:PRME) Reaches New 12-Month Low at $12.41

Prime Medicine, Inc. (NYSE:PRMEGet Rating) hit a new 52-week low on Friday . The company traded as low as $12.41 and last traded at $12.41, with a volume of 86500 shares trading hands. The stock had previously closed at $13.21.

Analyst Ratings Changes

Separately, started coverage on shares of Prime Medicine in a report on Thursday. They issued a “sell” rating for the company.

Prime Medicine Stock Performance

The company’s fifty day moving average is $17.06.

Prime Medicine Company Profile

(Get Rating)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Read More

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with's FREE daily email newsletter.